Our ability to identify, build and develop value added, innovative brands has always been a key advantage. We have a track record of successfully executing complex regulatory Rx-to-OTC switches, most recently with the pan-European switch of a contraceptive product in 2015.We are proud to be 1 of the 3 companies having successfully gained non-prescription status through the centralised procedure. This valuable and rare Rx-to-OTC expertise is one of our major competitive advantage in the industry.
Within the next several years we plan to leverage our strong operational, and regulatory capabilities, as well as our solid experience in innovative Rx-to-OTC switches, to launch novel brands that have the potential to become leaders in productive self care markets.
In addition to the core activities within the pharmaceutical and business value chain, from product development to marketing which we conduct in-house, we partner with specialised public and private organisations for innovative development programs and outsource the manufacturing of all of our products and their ingredients with experienced third party contract manufacturers. This make our supply chain lean and our business highly scalable. We also partner with reputed pharmaceutical companies to make our products available in over 90 countries worldwide. These close partnerships with industry experts are essential to our success, and we will continue to work closely with them to build and develop new solutions that meet our customers’ evolving needs.